Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback